Analysis of Soufflé Therapeutics™ Announces Oversubscribed $135 Million Series B Financing to Advance Lead Clinical Programs and Continued Pipeline Progress | FinancialContent - aVenture Research
financialcontent.com
Soufflé Therapeutics™ Announces Oversubscribed $135 Million Series B Financing to Advance Lead Clinical Programs and Continued Pipeline Progress | FinancialContent
SOUFFLÉ THERAPEUTICS, INC. (“Soufflé™” or “Company”), a leading RNA therapies company aimed at advancing the next generation of therapies designed to help people live healthier lives, today announced the close of an oversubscribed $135 million Series B financing. The round was led by Juvia Group and welcomes leading institutional investors TCG Crossover Management, BB Biotech, Fidelity Management & Research Company, Balyasny Asset Management, and a Leading Sovereign Wealth Fund, to